Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer NIAGARA
Phase II Trial of Intravesical Gemcitabine and MK-3475 Pembrolizumab in the Treatment of Patients with BCGUnresponsive Non-Muscle Invasive Bladder Cancer
A Phase I/II Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Na�ve or Received Incomplete BCG Treatment LEGEND STUDY
Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative with Evident Efficacy in Patients with Muscle Invasive Bladder Cancer
A Phase III, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer IR-NMIBC Following Transurethral Resection of Bladder Tumor TURBT
The Role of Bladder Cancer TAS2R38 Expression on Chemotherapy-Induced Bitter Taste
Study Type: Supportive Care
Phase: Feasibility/Pilot
NCTID: NCT04567719
Principal Investigator:
Elizabeth Wulff-Burchfield
METRICS Study: Metabolic Evaluation Through Resting Indirect Calorimetry in Bladder Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT06721260
Principal Investigator:
Jill Hamilton-Reeves